9MW1911 vs astegolimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: ST2 (IL1RL1) · full Chronic Obstructive Pulmonary Disease pipeline

9MW1911

Developed by Mabwell Bioscience

Phase 2 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Weak signal

NCT05803902 · Phase 1 · completed

The study was randomized and blinded with a placebo comparator, but it was conducted in healthy volunteers purely to check safety and dosing rather than to test whether the drug works in patients. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse Event(including serious adverse event)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2027 · NCT07292714 (registry estimate)

Reported efficacy

Adverse Event(including serious adverse event) (Day0-Day113): Safe and well tolerated across the doses studied: most adverse events were mild to moderate and resolved without treatment, no dose-related adverse events were observed, the only serious adverse event (fetal malformation) was judged unrelated to study drug, and there were no deaths or discontinuations due to adverse events.

Result source: NCT05803902

astegolimab

Developed by Roche

Phase 3 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Partial signal

NCT05595642 · Phase 3 · completed

This was a large (about 1,290 participants), randomized, double-blind, placebo-controlled trial measuring a clinically meaningful outcome (exacerbation rate), which is a strong design. However, the reported result shows only a numerical 14.5% reduction in exacerbations that did not reach statistical significance, meaning the trial did not demonstrate a clear treatment benefit despite its rigorous design.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2027 · NCT05878769 (registry estimate)

Reported efficacy

Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period (52 weeks): ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant (missed)

Result source: NCT05595642

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpoint9MW1911astegolimab
Moderate or severe exacerbations, annualised rate—Not reported—Not posted · NCT05595642
Trough FEV1, change—Not reported—Not posted · NCT05595642
SGRQ total, change—Not reported57.7 vs 63.3−5.6 vs placebowk 48 · n 42NCT03615040
4 other results
  • 59.5 vs 59.5 wk 36 · n 42 · Phase 2 · secondary NCT03615040
  • 56.6 vs 59.6 wk 24 · n 42 · Phase 2 · secondary NCT03615040
  • 56.9 vs 59.9 wk 12 · n 42 · Phase 2 · secondary NCT03615040
  • 56.7 vs 58.9 wk 4 · n 42 · Phase 2 · secondary NCT03615040
TDI focal score—Not reported—Not posted · NCT05595642

Moderate or severe exacerbations, annualised rate

9MW1911
—Not reported
astegolimab
—Not posted · NCT05595642

Trough FEV1, change

9MW1911
—Not reported
astegolimab
—Not posted · NCT05595642

SGRQ total, change

9MW1911
—Not reported
astegolimab
57.7 vs 63.3−5.6 vs placebowk 48 · n 42NCT03615040
4 other results
  • 59.5 vs 59.5 wk 36 · n 42 · Phase 2 · secondary NCT03615040
  • 56.6 vs 59.6 wk 24 · n 42 · Phase 2 · secondary NCT03615040
  • 56.9 vs 59.9 wk 12 · n 42 · Phase 2 · secondary NCT03615040
  • 56.7 vs 58.9 wk 4 · n 42 · Phase 2 · secondary NCT03615040

TDI focal score

9MW1911
—Not reported
astegolimab
—Not posted · NCT05595642
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

9MW1911: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. 9MW1911: 0 of 4 rows · astegolimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricastegolimab
Dropout rate
14.3%a
NCT03615040 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03615040 · Phase 2 · registry result, not featured evidence
Serious AEs
28.6%a
NCT03615040 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
headache 23.8% (placebo 12.8%)
urinary tract infection 14.3% (placebo 2.6%)
chest pain 11.9% (placebo 10.3%)
NCT03615040 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

astegolimab

Moderate or Severe Exacerbation Rate Annualized 2.21 vs 2.67 placebo Exacerbations @ 48wk
event rate · Exacerbations
NCT03615040 · Phase 2 · registry result, not featured evidence
SGRQ Total 56.7 vs 58.9 placebo score @ 4wk
absolute change · score
NCT03615040 · Phase 2 · registry result, not featured evidence
show 4 more results
56.9 vs 59.9 placebo score @ 12wk
NCT03615040 · Phase 2 · registry result, not featured evidence
56.6 vs 59.6 placebo score @ 24wk
NCT03615040 · Phase 2 · registry result, not featured evidence
59.5 vs 59.5 placebo score @ 36wk
NCT03615040 · Phase 2 · registry result, not featured evidence
57.7 vs 63.3 placebo score @ 48wk
NCT03615040 · Phase 2 · registry result, not featured evidence
CAT Total 22.1 vs 22.6 placebo score @ 0wk
absolute change · score
NCT03615040 · Phase 2 · registry result, not featured evidence
show 5 more results
22.2 vs 21.7 placebo score @ 4wk
NCT03615040 · Phase 2 · registry result, not featured evidence
22 vs 22.3 placebo score @ 12wk
NCT03615040 · Phase 2 · registry result, not featured evidence
22.7 vs 22.1 placebo score @ 24wk
NCT03615040 · Phase 2 · registry result, not featured evidence
22.7 vs 22.4 placebo score @ 36wk
NCT03615040 · Phase 2 · registry result, not featured evidence
23.4 vs 23.6 placebo score @ 48wk
NCT03615040 · Phase 2 · registry result, not featured evidence
mMRC Dyspnea Scale 2 vs 2 placebo score @ 0wk
absolute change · score
NCT03615040 · Phase 2 · registry result, not featured evidence
show 5 more results
2 vs 2 placebo score @ 4wk
NCT03615040 · Phase 2 · registry result, not featured evidence
2 vs 2 placebo score @ 12wk
NCT03615040 · Phase 2 · registry result, not featured evidence
2 vs 2 placebo score @ 24wk
NCT03615040 · Phase 2 · registry result, not featured evidence
2 vs 3 placebo score @ 36wk
NCT03615040 · Phase 2 · registry result, not featured evidence
2 vs 2 placebo score @ 48wk
NCT03615040 · Phase 2 · registry result, not featured evidence
VAS Dyspnea Cough Sputum 129.3 vs 148.5 placebo score @ 4wk
absolute change · score
VAS Total Week 4
NCT03615040 · Phase 2 · registry result, not featured evidence
VAS Dyspnea Cough Sputum 139.5 vs 140 placebo score @ 12wk
absolute change · score
VAS Total Week 12
NCT03615040 · Phase 2 · registry result, not featured evidence
VAS Dyspnea Cough Sputum 131 vs 146.6 placebo score @ 24wk
absolute change · score
VAS Total Week 24
NCT03615040 · Phase 2 · registry result, not featured evidence
VAS Dyspnea Cough Sputum 146.9 vs 147.6 placebo score @ 36wk
absolute change · score
VAS Total Week 36
NCT03615040 · Phase 2 · registry result, not featured evidence
VAS Dyspnea Cough Sputum 140.7 vs 146.5 placebo score @ 48wk
absolute change · score
VAS Total Week 48
NCT03615040 · Phase 2 · registry result, not featured evidence
Dyspnea VAS 50.1 vs 57.8 placebo score @ 4wk
absolute change · score
VAS Dyspnoea Week 4
NCT03615040 · Phase 2 · registry result, not featured evidence
Dyspnea VAS 55.2 vs 54.7 placebo score @ 12wk
absolute change · score
VAS Dyspnoea Week 12
NCT03615040 · Phase 2 · registry result, not featured evidence
Dyspnea VAS 46.5 vs 57.9 placebo score @ 24wk
absolute change · score
VAS Dyspnoea Week 24
NCT03615040 · Phase 2 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 9MW1911's landscape · astegolimab's landscape